Key Points
- Insider selling: Mayukh Sukhatme sold 144,756 Roivant Sciences shares for approximately $5.28 million, reducing his position by 0.77% while retaining 18.63 million shares. Including five other sales in August, his disclosed sales totaled more than $36.5 million.
- Mixed financial results: Roivant reported a quarterly loss of $0.26 per share, beating estimates for a $0.30 loss, but revenue of $1.44 million fell short of the $2.06 million forecast. The company continues to report significant losses and analysts expect a full-year loss of $2 per share.
- Analyst sentiment remains favorable: Roivant has a consensus “Moderate Buy” rating, with recent price-target increases from HC Wainwright and Citigroup to $41 and $46, respectively. However, the average consensus target of $35.14 is below the stock’s reported $36.30 price.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 17,519 shares of Roivant Sciences stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $37.30, for a total transaction of $653,458.70. Following the completion of the transaction, the insider directly owned 18,630,739 shares of the company's stock, valued at approximately $694,926,564.70. This represents a 0.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Mayukh Sukhatme also recently made the following trade(s):
- On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The shares were sold at an average price of $36.48, for a total transaction of $5,280,698.88.
- On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The stock was sold at an average price of $37.17, for a total transaction of $6,426,655.83.
- On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total transaction of $8,810,302.71.
- On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75.
- On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total transaction of $5,029,879.66.
Roivant Sciences Stock Performance
NASDAQ ROIV opened at $36.30 on Friday. Roivant Sciences Ltd. has a one year low of $11.60 and a one year high of $37.97. The company has a 50-day simple moving average of $34.61 and a 200-day simple moving average of $30.43. The firm has a market capitalization of $26.22 billion, a PE ratio of -68.49 and a beta of 1.12.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. Equities analysts forecast that Roivant Sciences Ltd. will post -2 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of ROIV. UBS Group AG increased its stake in shares of Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company's stock valued at $399,080,000 after purchasing an additional 15,645,836 shares during the period. Morgan Stanley boosted its position in shares of Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company's stock worth $1,266,402,000 after buying an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Roivant Sciences by 365.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company's stock worth $238,323,000 after buying an additional 8,621,567 shares during the period. Norges Bank bought a new position in Roivant Sciences in the 4th quarter worth approximately $112,750,000. Finally, Jefferies Financial Group Inc. bought a new position in Roivant Sciences in the 4th quarter worth approximately $76,272,000. 64.76% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on the company. TD Cowen reiterated a "buy" rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Sanford C. Bernstein upgraded Roivant Sciences to a "strong-buy" rating in a research report on Wednesday, July 29th. HC Wainwright boosted their price objective on Roivant Sciences from $34.00 to $41.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Citigroup upped their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Finally, Bank of America reaffirmed a "neutral" rating on shares of Roivant Sciences in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $35.14.
Get Our Latest Research Report on Roivant Sciences
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
